[DOI] [PMC free article] [PubMed] [Google Scholar] 186.Bao LH, Zhang YN, Zhang JN, et al
Whether a pharmacy may compound BPC-157 right now turns on a separate FDA policy
10.1016/j.heliyon.2024.e27074 126 ParasharP.MazharI.KanoujiaJ.YadavA.KumarP.SarafS
Signs Your Dose May Need Adjustment Signs Your Dose May Be Too Low No improvement in sleep quality after 3-4 weeks Minimal energy changes after 6-8 weeks Lab work shows IGF-1 levels unchanged from baseline Signs Your Dose May Be Too High Water retention (puffy hands, ankles, face) Tingling or numbness in extremities Joint stiffness or discomfort Headaches, particularly in the morning Carpal tunnel-like symptoms If you experience these symptoms, contact your provider
It is the only FDA-approved compound specifically targeting visceral adipose tissue reduction in clinical studies
Off-Label Dosing Protocols Used in Clinical Practice Because no clinical trials have established human dosing, all dosing information below reflects empirical protocols used by peptide-prescribing clinicians
